糖尿病外围神经病变中的线粒体动态:发病,进展和治疗方法
Honghai Yu1, Cunqing Yang2,3, Guoqiang Wang4
1Department of Traditional Chinese Medicine, Hunan University of Medicine General Hospital, Huaihua, Hunan Province, China.
Medicine
|July 23, 2025
概括
糖尿病外围神经病变 (DPN) 涉及糖尿病中复杂的神经损伤. 对神经元健康至关重要的线粒体动力学与DPN有关,这表明新的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 细胞生物学 细胞生物学
背景情况:
- 糖尿病外围神经病变 (DPN) 是糖尿病的严重并发症,引起疼痛,并可能导致截肢.
- 目前对DPN的治疗方法是不可逆转的,这凸显了对新型治疗策略的需求.
- 驱动DPN病变的确切机制,尽管进行了广泛的研究,但仍未完全理解.
研究的目的:
- 讨论与DPN相关的病理生理变化.
- 探索线粒体动力学在DPN病变发生中的作用.
- 审查目前针对DPN的针对性线粒体疗法.
主要方法:
- 对DPN病理生理学现有文献的综述.
- 分析线粒体动力学 (裂变和融合) 在高血糖条件下的神经元健康中的作用.
- 讨论线粒体失调如何导致DPN进展.
主要成果:
- 线粒体分裂和融合蛋白的失调越来越被认为是DPN的关键病理机制.
- 线粒体动力学的不平衡会破坏细胞代谢,能量生产和细胞亡,导致神经元功能障碍.
- 线粒体动力学对于在高葡萄糖条件下维持神经元平衡至关重要.
结论:
- 线粒体动力学在糖尿病外围神经病变的发病过程中发挥着重要作用.
- 准线粒体通路为开发更有效的DPN治疗提供了一个有希望的途径.
- 对线粒体动力学的进一步研究可以导致改善DPN的干预策略.
相关概念视频
Pathophysiology of Diabetes
1.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K
Mitochondrial Membranes
12.4K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
12.4K
Diabetes: Management and Pharmacotherapy
399
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
399
Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Parkinson's Disease: Overview
713
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
713


